Biocept Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept or view top-rated stocks.

Wall Street analysts have given Biocept a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biocept wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Biocept saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 969,600 shares, an increase of 29.7% from the August 15th total of 747,600 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 0.8 days.
View Biocept's Short Interest.

Biocept is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Biocept.

Biocept, Inc. (NASDAQ:BIOC) issued its quarterly earnings results on Sunday, August, 15th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $12.05 million for the quarter. Biocept had a negative net margin of 4.02% and a negative trailing twelve-month return on equity of 8.71%.
View Biocept's earnings history.

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOC shares have increased by 3.2% and is now trading at $3.89.
View which stocks have been most impacted by COVID-19.

Shares of Biocept reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

1 brokers have issued 12-month price targets for Biocept's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 414.1% from the stock's current price.
View analysts' price targets for Biocept or view top-rated stocks among Wall Street analysts.

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Biocept include Exagen (XGN), Centogene (CNTG), Enzo Biochem (ENZ), Viridian Therapeutics (VRDN), OpGen (OPGN), Progenity (PROG), Vyant Bio (VYNT), AnPac Bio-Medical Science (ANPC), Psychemedics (PMD), CannLabs (CANL), PharmChem (PCHM), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX) and CBA Florida (CBAI).
View all of BIOC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Biocept's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.91%), Morgan Stanley (1.33%), Morgan Stanley (1.21%), GSA Capital Partners LLP (1.13%), Geode Capital Management LLC (1.01%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends for Biocept.

BIOC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Vanguard Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Biocept or view top insider-selling stocks.

BIOC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, GSA Capital Partners LLP, State Street Corp, Virtu Financial LLC, Susquehanna International Group LLP, Geode Capital Management LLC, and Sabby Management LLC.
View insider buying and selling activity for Biocept or or view top insider-buying stocks.

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $3.89.

Biocept has a market capitalization of $57.27 million and generates $27.46 million in revenue each year.

Biocept employs 107 workers across the globe.

The official website for Biocept is www.biocept.com.

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200 or via email at [email protected].